United States

GenVec board restructures operations, withdraws plan of dissolution

Wednesday, September 4, 2013 12:11 PM

The board of directors of GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has withdrawn the Plan of Complete Liquidation and Dissolution for the company, previously adopted May 24.

More... »

ClinEdge, ClinicalConnection partner

Wednesday, September 4, 2013 12:03 PM

ClinEdge, a Boston-based full-service marketing, patient recruitment and clinical operations firm, has partnered with database company ClinicalConnection and ClinicalConnection.com, a web site for clinical trial searches, notifications and patient referrals. More than 250,000 people visit ClinicalConnection.com each month.

More... »

Neurotrope completes reverse merger

Wednesday, September 4, 2013 11:58 AM

Nevada-based Neurotrope (formerly BlueFlash Communications) has completed a reverse merger in which Neurotrope BioScience, based in Delaware, became a wholly owned subsidiary of the company.

More... »

Mount Sinai, Exosome Diagnostics partner

Friday, August 30, 2013 02:29 PM

The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics are collaborating on the R&D of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The five-year agreement will allow the companies to establish targeted research and biomarker discovery programs in oncology and inflammation. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.

More... »

Endo to acquire Boca Pharmacal

Friday, August 30, 2013 02:29 PM

Endo Health Solutions, a U.S.-based specialty healthcare company, will acquire privately-held Boca Pharmacal, a specialty generics company, for $225 million in cash. Boca Pharmacal focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.

More... »

Meda acquires Acton Pharmaceuticals

Friday, August 30, 2013 02:27 PM

Meda, an international specialty pharmaceutical company, has acquired Acton Pharmaceuticals for $135 million, plus a milestone payment of $10 million and royalties. The acquisition is expected to close during the fourth quarter and is subject to customary closing conditions and U.S. regulatory approval. Existing credit facilities will fund the acquisition.

More... »

Idera Pharmaceuticals, NCI collaborate

Friday, August 30, 2013 02:25 PM

Idera Pharmaceuticals entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the company’s Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas.

More... »

International Stem Cell, Duke collaborate on Parkinson's disease

Friday, August 30, 2013 02:22 PM

International Stem Cell (ISCO), a California-based biotechnology company developing novel stem cell-based therapies, has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's neural stem cell product.

More... »

Rho awarded for workplace effectiveness, flexibility

Thursday, August 29, 2013 12:00 PM

CRO Rho has received the 2013 Alfred P. Sloan Award for Excellence in Workplace Effectiveness and Flexibility. 

More... »

Evotec, Jain Foundation extend research collaboration

Thursday, August 29, 2013 11:00 AM

Evotec, a drug discovery alliance and development partnership company, and privately funded nonprofit the Jain Foundation have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.

More... »